Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

PHASE2CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Secukinmab

Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

DRUG

Placebo

Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

Trial Locations (58)

500

Novartis Investigative Site, Changhua

1062

Novartis Investigative Site, Budapest

1200

Novartis Investigative Site, Brussels

4032

Novartis Investigative Site, Debrecen

5700

Novartis Investigative Site, Gyula

14059

Novartis Investigative Site, Berlin

14609

Novartis Investigative Site, Rochester

22081

Novartis Investigative Site, Hamburg

22415

Novartis Investigative Site, Hamburg

29601

Novartis Investigative Site, Greenville

31134

Novartis Investigative Site, Hildesheim

38305

Novartis Investigative Site, Jackson

40201

Novartis Investigative Site, Taichung

40447

Novartis Investigative Site, Taichung

40705

Novartis Investigative Site, Taichung

49048

Novartis Investigative Site, Kalamazoo

53002

Novartis Investigative Site, Pardubice

62704

Novartis Investigative Site, Springfield

68516

Novartis Investigative Site, Lincoln

72200

Novartis Investigative Site, Ostrava

72205

Novartis Investigative Site, Little Rock

73103

Novartis Investigative Site, Oklahoma City

80639

Novartis Investigative Site, München

81346

Novartis Investigative Site, Kaohsiung City

83301

Novartis Investigative Site, Niaosong Township

83814

Novartis Investigative Site, Coeur d'Alene

85202

Novartis Investigative Site, Mesa

85381

Novartis Investigative Site, Peoria

90404

Novartis Investigative Site, Santa Monica

95445

Novartis Investigative Site, Bayreuth

115522

Novartis Investigative Site, Moscow

117049

Novartis Investigative Site, Moscow

129327

Novartis Investigative Site, Moscow

150003

Novartis Investigative Site, Yaroslavl

170036

Novartis Investigative Site, Tver'

190068

Novartis Investigative Site, Saint Petersburg

194104

Novartis Investigative Site, Saint Petersburg

195257

Novartis Investigative Site, Saint Petersburg

300053

Novartis Investigative Site, Tula

74135-2920

Novartis Investigative Site, Tulsa

686 01

Novartis Investigative Site, Uherské Hradiště

128 50

Novartis Investigative Site, Prague

820-8505

Novartis Investigative Site, Iizuka

650-0044

Novartis Investigative Site, Kobe

658-0011

Novartis Investigative Site, Kobe

228-8522

Novartis Investigative Site, Sagamihara

710-8522

Novartis Investigative Site, Kurashiki

350-1103

Novartis Investigative Site, Kawagoe

15-337

Novartis Investigative Site, Bialystok

15-461

Novartis Investigative Site, Bialystok

20-607

Novartis Investigative Site, Lublin

040 15

Novartis Investigative Site, Košice

921 12

Novartis Investigative Site, Piešťany

975 17

Novartis Investigative Site, Banská Bystrica

602-739

Novartis Investigative Site, Busan

431-070

Novartis Investigative Site, Anyang-si

137-701

Novartis Investigative Site, Seoul

143-729

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY